B+
Bull case
25%
Probability
Target price
$36.00
Analysis reference price unavailable
Analysis 2026-05-15 · RankAlpha Sentiment Codex
QURE
uniQureFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The company source supports a still-constructive monitoring thesis: AMT-130 retains an active regulatory path, the UK filing remains targeted for Q3 2026, AMT-260 has a dated June catalyst, and cash runway into 2H29 reduces immediate financing pressure [#8-K-2026-05-05].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +0.9.
What can break
AMT-191 has dose-limiting toxicity concerns: additional mid- and high-dose dosing remains paused pending evaluation of asymptomatic Grade 3 liver enzyme elevations in two patients [#8-K-2026-05-05].
Momentum
82
Value
41
Sentiment
22
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $30.00 · Bull $36.00 · Bear $20.00Analysis 2026-05-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-21
Investment thesis
As of 2026-09-21
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-21. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $68.00
Why
Momentum82 · Δ7d -10.6
Value41 · Δ7d 0.0
Sentiment22 · Δ7d +0.9
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +0.9.
Contradictions & invalidation
- • AMT-191 has dose-limiting toxicity concerns: additional mid- and high-dose dosing remains paused pending evaluation of asymptomatic Grade 3 liver enzyme elevations in two patients [#8-K-2026-05-05].
- • External analyst and news coverage remains thin, which lowers confidence in post-earnings read-through and makes sentiment more headline-sensitive.
- • The key post-print overhang did not change: FDA said existing Phase I/II data versus external control are not sufficient as primary evidence of effectiveness for AMT-130, implying a potentially longer and costlier U.S.
Catalyst clock
2026-05-20
Post-earnings digestion tests whether Q1 updates can hold the stock above pre-print levels
Lead driver: Sentiment · See AI snapshot
Momentum
82
9% active weight
Current posture
7d trendFlat
Δ7d
-10.6
Δ21d
-11.3
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.0
Sentiment
22
62% active weight
Current posture
7d trendFlat
Δ7d
+0.9
Δ21d
+9.7
Why this grade
Composite grade F. Momentum 82.3 / Value 41.2 / Sentiment 22.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-15. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$30.00
Analysis reference price unavailable
Analysis 2026-05-15 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$20.00
Analysis reference price unavailable
Analysis 2026-05-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$3.33B
Beta
0.67
Shares Out
69.37M
P/E (TTM) · Derived
-13.9
P/S (TTM)
89.50
P/FCF (TTM) · Derived
-18.36
Rev YoY
+11.0%
EPS YoY
+77.8%
Gross Margin
+15.0%
Op Margin
-1093.2%
Net Debt
-$85.95M
Current Ratio
10.01
As of 2026-09-21 • Updated nightlySource: Internal modelMethods & Data